Exposure to environmental toxicants and pathogenesis of amyotrophic lateral sclerosis: State of the art and research perspectives

International Journal of Molecular Sciences

Volumn 14, Issue 8, 2013, Pages 15286-15311

  Trojsi, Francesca ^a,b   Monsurrò, Maria Rosaria ^a,b   Tedeschi, Gioacchino ^a,b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Neurological Institute for Diagnosis and Care Hermitage Capodimonte   (Italy)

Author keywords

Amyotrophic lateral sclerosis; Cyanobacteria; Environmental toxicants; Heavy metals; Lead; Methylmercury; Neurodegeneration; Organophosphates; Pesticides; Selenium

Indexed keywords

2 AMINO 3 METHYLAMINOPROPIONIC ACID; COPPER; ENVIRONMENTAL CHEMICAL; HEAVY METAL; LEAD; MERCURY; ORGANOPHOSPHATE PESTICIDE; PESTICIDE; SELENIUM; TOXIC SUBSTANCE; ZINC;

AGING; AMYOTROPHIC LATERAL SCLEROSIS; BIOACCUMULATION; CYANOBACTERIUM; CYCADOPHYTA; DEGENERATIVE DISEASE; DIETARY INTAKE; DISEASE ASSOCIATION; ELECTRIC POWER PLANT; ELECTRIC SHOCK; ELECTROMAGNETIC FIELD; ELECTRONICS INDUSTRY; ENVIRONMENTAL EXPOSURE; EPIGENETICS; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; INDUSTRIAL WORKER; MORTALITY; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; OCCUPATIONAL EXPOSURE; PATHOGENESIS; REVIEW; RISK FACTOR; SMOKING;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CYANOBACTERIA; ENVIRONMENTAL EXPOSURE; HAZARDOUS SUBSTANCES; HUMANS; METALS, HEAVY; MICE; PESTICIDES; PROTEIN FOLDING; RISK FACTORS;

EID: 84880706463     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms140815286     Document Type: Review

References (192)

1. Kiernan, M.C.; Vucic, S.; Cheah, B.C.; Turner, M.R.; Eisen, A.; Hardiman, O.; Burrell, J.R.; Zoing M.C. Amyotrophic lateral sclerosis. Lancet 2011, 6736, 61156-61157.
2. Ludolph, A.C.; Brettschneider, J.; Weishaupt, J.H. Amyotrophic lateral sclerosis. Curr. Opin. Neurol. 2012, 25, 530-535.
3. Soo, K.Y.; Farg, M.; Atkin, J.D. Molecular motor proteins and amyotrophic lateral sclerosis. Int. J. Mol. Sci. 2011, 12, 9057-9082.
4. Ido, A.; Fukuyama, H.; Urushitani, M. Protein misdirection inside and outside motor neurons in amyotrophic lateral sclerosis (ALS): A possible clue for therapeutic strategies. Int. J. Mol. Sci. 2011, 12, 6980-7003.
5. Rosen, D.R.; Siddique, T.; Patterson, D.; Figlewicz, D.A.; Sapp, P.; Hentati, A.; Donaldson, D.; Goto, J.; O'Regan, J.P.; Deng, H.X. et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362, 59-62.
6. Neumann, M. Molecular neuropathology of TDP-43 proteinopathies. Int. J. Mol. Sci. 2009, 10, 232-246.
7. Gawel, M.; Zaiwalla, Z.; Rose, C.F. Antecedent events in motor neuron disease. J. Neurol. Neurosurg. Psychiatry 1983, 46, 1041-1043.
8. Deapen, D.M.; Henderson, B.E. A case-control study of amyotrophic lateral sclerosis. Am. J.Epidemiol. 1986, 123, 790-799.
9. Johansen, C. Exposure to electromagnetic fields and risk of central nervous system disease in utility workers. Epidemiology 2000, 11, 539-543.
10. Hakansson, N.; Gustavsson, P.; Johansen, C.; Floderus, B. Neurodegenerative diseases in welders and other workers exposed to high levels of magnetic fields. Epidemiology 2003, 14, 420-426.
11. Qureshi, M.M.; Hayden, D.; Urbinelli, L.; Ferrante, K.; Newhall, K.; Myers, D.; Hilgenberg, S.; Smart, R.; Brown, R.H.; Cudkowicz, M.E. Analysis of factors that modify susceptibility and rate of progression in amyotrophic lateral sclerosis (ALS). Amyotroph. Lateral Scler. 2006, 7, 173-182.
12. Morahan, J.M.; Pamphlett, R. Amyotrophic lateral sclerosis and exposure to environmental toxins: An Australian case-control study. Neuroepidemiology 2006, 27, 130-135.
13. Steenland, K.; Hein, M.J.; Cassinelli, R.T., 2nd; Prince, M.M.; Nilsen, N.B.; Whelan, E.A.; Waters, M.A.; Ruder, A.M.; Schnorr, T.M. Polychlorinated biphenyls and neurodegenerative disease mortality in an occupational cohort. Epidemiology 2006, 17, 8-13.
14. Weisskopf, M.G.; Morozova, N.; O'Reilly, E.J.; McCullough, M.L.; Calle, E.E.; Thun, M.J.; Ascherio, A. Prospective study of chemical exposures and amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 2009, 80, 558-561.
15. Sutedja, N.A.; Veldink, J.H.; Fischer, K.; Kromhout, H.; Heederik, D.; Huisman, M.H.; Wokke, J.H.; van den Berg, L.H. Exposure to chemicals and metals and risk of amyotrophic lateral sclerosis: A systematic review. Amyotroph. Lateral Scler. 2009, 10, 302-309.
16. Johnson, F.O.; Atchison, W.D. The role of environmental mercury, lead and pesticide exposure in development of amyotrophic lateral sclerosis. Neurotoxicology 2009, 30, 761-765.
17. Vanacore, N.; Cocco, P.; Fadda, D.; Dosemeci, M. Job strain, hypoxia and risk of amyotrophic lateral sclerosis: Results from a death certificate study. Amyotroph. Lateral Scler. 2010, 11, 430-434.
18. Callaghan, B.; Feldman, D.; Gruis, K.; Feldman, E. The association of exposure to lead, mercury, and selenium and the development of amyotrophic lateral sclerosis and the epigenetic implications. Neurodegener. Dis. 2011, 8, 1-8.
19. Bradley, W.G.; Borenstein, A.R.; Nelson, L.M.; Codd, G.A.; Rosen, B.H.; Stommel, E.W.; Cox, P.A. Is exposure to cyanobacteria an environmental risk factor for amyotrophic lateral sclerosis and other neurodegenerative diseases? Amyotroph. Lateral Scler. Frontotemporal Degener. 2013, doi:10.3109/21678421.2012.750364.
20. Cox, P.A.; Sacks, O.W. Cycad neurotoxin, consumption of fruit bats, and ALS/PDC disease in Guam. Neurology 2002, 59, 1664-1665.
21. Miranda, M.L.; Galeano, M.A.O.; Tassone, E.; Allen, K.D.; Horner, R.D. Spatial analysis of the etiology of ALS among 1991 Gulf War veterans. Neurotoxicology 2008, 29, 964-970.
22. Horner, R.D.; Grambow, S.C.; Coffman, C.J.; Lindquist, J.H.; Oddone, E.Z.; Allen, K.D.; Kasarskis, E.J. Amyotrophic lateral sclerosis among 1991 Gulf War veterans: Evidence for a time-limited outbreak. Neuroepidemiology 2008, 31, 28-32.
23. Kisby, G.E.; Ellison, M.; Spencer, P.S. Content of the neurotoxins cycasin (methylazoxy-methanol beta-D-glucoside) and BMAA (beta-N-methylaminol-alanine) in cycad flour prepared by Guam Chamorros. Neurology 1992, 42, 1336-1340.
24. Murch, S.J.; Cox, P.A.; Banack, S.A. A mechanism for slow release of biomagnified cyanobacterial neurotoxins and neurodegenerative disease in Guam. Proc. Natl. Acad. Sci. USA 2004, 101, 12228-12231.
25. Kuzuhara, S. ALS/Parkinsonism-dementia complex of the Kii peninsula of Japan (Muro disease). Historical review, epidemiology and concept. Rinsho Shinkeigaku 2007, 47, 962-965.
26. Bradley, W.G.; Cox, P.A. Beyond Guam: BMAA and sporadic amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2009, 10, 5-6.
27. Haley, R.W. Excess incidence of ALS in young Gulf War veterans. Neurology 2003, 61, 750-756.
28. Kasarskis, E.J.; Lindquist, J.H.; Coffman, C.J.; Grambow, S.C.; Feussner, J.R.; Allen, K.D.; Oddone, E.Z.; Kamins, K.A.; Horner, R.D.; Als Gulf War Clinical Review Team. Clinical aspects of ALS in Gulf War veterans. Amyotroph. Lateral Scler. 2009, 10, 35-41.
29. Haley, R.W.; Billecke, S.; La Du, B.N. Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans. Toxicol. Appl. Pharmacol. 1996, 157, 227-233.
30. Mackness, B.; Durrington, P.N.; Mackness, M.I. Low paraoxonase in Persian Gulf War Veterans self-reporting Gulf War Syndrome. Biochem. Biophys. Res. Commun. 2000, 276, 729-733.
31. Page, W.F.; Mahan, C.M.; Bullman, T.A.; Kang, H.K. Health effects in Army Gulf War veterans possibly exposed to chemical munitions destruction at Khamisiyah, Iraq. Part I. Morbidity associated with potential exposure. Mil. Med. 2005, 170, 935-944.
32. Bullman, T.A.; Mahan, C.M.; Kang, H.K.; Page, W.F. Mortality in US Army Gulf War veterans exposed to 1991 Khamisiyah chemical munitions destruction. Am. J. Public. Health 2005, 95, 1382-1388.
33. Proctor, S.P.; Heaton, K.J.; Heeren, T.; White, R.F. Effects of sarin and cyclosarin exposure during the 1991 Gulf War on neurobehavioral functioning in US army veterans. Neurotoxicology 2006, 27, 931-939.
34. Heaton, K.J.; Palumbo, C.L.; Proctor, S.P.; Killiany, R.J.; Yurgelun-Todd, D.A.; White, R.F. Quantitative magnetic resonance brain imaging in US army veterans of the 1991 Gulf War potentially exposed to sarin and cyclosarin. Neurotoxicology 2007, 28, 761-769.
35. Cox, P.A.; Richer, R.; Metcalf, J.S.; Banack, S.A.; Codd, G.A.; Bradley, W.G. Cyanobacteria and BMAA exposure from desert dust: A possible link to sporadic ALS among Gulf War veterans. Amyotroph. Lateral Scler. 2009, 10, 109-117.
36. Metcalf, J.S.; Richer, R.; Cox, P.A.; Codd, G.A. Cyanotoxins in desert environments may present a risk to human health. Sci. Total Environ. 2012, 421-422, 118-123.
37. Cox, P.A.; Banack, S.A. A non-protein amino acid and neurodegeneration. Science 2006, 314, 1242.
38. Bell, E.A. The discovery of BMAA, and examples of biomagnification and protein incorporation involving other non-protein amino acids. Amyotroph. Lateral Scler. 2009, 10, 21-25.
39. Karlsson, O.; Roman, E.; Berg, A.L.; Brittebo, E.B. Early hippocampal cell death, and late learning and memory deficits in rats exposed to the environmental toxin BMAA (beta-N-methylamino-L-alanine) during the neonatal period. Behav. Brain Res. 2011, 219, 310-320.
40. Karlsson, O.; Berg, A.L.; Lindström, A.K.; Hanrieder, J.; Arnerup, G.; Roman, E.; Bergquist, J.; Lindquist, N.G.; Brittebo, E.B.; Andersson, M. Neonatal exposure to the cyanobacterial toxin BMAA induces changes in protein expression and neurodegeneration in adult hippocampus. Toxicol. Sci. 2012, 130, 391-404.
41. Blake, N.M.; Kirk, R.L.; Wilson, S.R.; Garruto, R.M.; Gajdusek, D.C.; Gibbs, C.J., Jr.; Hoffman, P. Search for a red cell enzyme or serum protein marker in amyotrophic lateral sclerosis and parkinsonism-dementia of Guam. Am. J. Med. Genet. 1983, 14, 299-305.
42. Garruto, R.M.; Plato, C.C.; Myrianthopoulos, N.C.; Schanfield, M.S.; Gajdusek, D.C. Blood groups, immunoglobulin allotypes and dermatoglyphic features of patients with amyotrophic lateral sclerosis and parkinsonism-dementia of Guam. Am. J. Med. Genet. 1983, 14, 289-298.
43. Plato, C.C.; Garruto, R.M.; Galasko, D.; Craig, U.K.; Plato, M.; Gamst, A.; Torres, J.M.; Wiederholt, W. Amyotrophic lateral sclerosis and parkinsonism-dementia complex of Guam: Changing incidence rates during the past 60 years. Am. J. Epidemiol. 2003, 157, 149-157.
44. Kurland, L.T.; Mulder, D.W. Epidemiologic investigations of amyotrophic lateral sclerosis. I. Preliminary report on geographic distribution, with particular reference to the Mariana Islands, including clinical and pathologic observations. Neurology 1954, 4, 338-348.
45. Whiting, M.G. Food practices in ALS foci in Japan, the Marianas, and New Guinea. Fed. Proc. 1964, 23, 1343-1345.
46. Whiting, M.; Spatz, M.; Matsumoto, H. Research progress on cycads. Econ. Bot. 1966, 20, 98-102.
47. Duncan, M.W.; Kopin, I.J.; Garruto, R.M.; Lavine, L.; Markey, S.P. 2-Amino-3 (methylamino)-propionic acid in cycad-derived foods is an unlikely cause of amyotrophic lateral sclerosis/Parkinsonism. Lancet 1988, 2, 631-632.
48. Banack, S.A.; Cox, P.A. Biomagnification of cycad neurotoxins in flying foxes: Implications for ALS-PDC in Guam. Neurology 2003, 61, 387-389.
49. Cox, P.A.; Banack, S.A.; Murch, S.J. Biomagnification of cyanobacterial neurotoxins and neurodegenerative disease among the Chamorro people of Guam. Proc. Natl. Acad. Sci. USA 2003, 100, 13380-13383.
50. Banack, S.A.; Murch, S.J.; Cox, P.A. Neurotoxic flying foxes as dietary items for the Chamorro people, Marianas Islands. J. Ethnopharmacol. 2006, 106, 97-104.
51. Xie, X.; Mondo, K.; Basile, M.J.; Bradley, W.G.; Mash, D.C. Tracking Brain Uptake and Protein Incorporation of Cyanobacterial Toxin BMAA. In Proceedings of the 22nd International Symposium on ALS/MND, Sydney, Australia, 30 November-2 December 2011; Informa Healthcare: Stockholm, Sweden, 2011.
52. Rodgers, K.; Dunlop, R. The Cyanobacteria-Derived BMAA Can Be Incorporated into Cell Proteins and Ccould thus Be an Environmental Trigger for ALS and Other Neurological Diseases Associated with Protein Misfolding. In Proceedings of the 22nd International Symposium on ALS/MND, Sydney, Australia, 30 November-2 December 2011; Informa Healthcare: Stockholm, Sweden, 2011.
53. Pablo, J.; Banack, S.A.; Cox, P.A.; Johnson, T.E.; Papapetropoulos, S.; Bradley, W.G.; Buck, A.; Mash, D.C. Cyanobacterial neurotoxin BMAA in ALS and Alzheimer's disease. Acta Neurol. Scand. 2009, 120, 216-225.
54. Esterhuizen, M.; Downing, T.G. Beta-N-methylamino-L-alanine (BMAA) in novel South African cyanobacterial isolates. Ecotoxicol. Environ. Saf. 2008, 71, 309-313.
55. Banack, S.A.; Johnson, H.E.; Cheng, R.; Cox, P.A. Production of the neurotoxin BMAA by a marine cyanobacterium. Mar. Drugs 2007, 5, 180-196.
56. Jonasson, S.; Eriksson, J.; Berntzon, L.; Spácil, Z.; Ilag, L.L.; Ronnevi, L.O.; Rasmussen, U.; Bergman, B. Transfer of a cyanobacterial neurotoxin within a temperate aquatic ecosystem suggests pathways for human exposure. Proc. Natl. Acad. Sci. USA 2010, 18, 9252-9257.
57. Brand, L.E.; Pablo, J.; Compton, A.; Hammerschlag, N.; Mash, D.C. Cyanobacterial blooms and the occurrence of the neurotoxin, beta-N-methylamino-L-alanine (BMAA), in South Florida aquatic food webs. Harmful Algae 2010, 9, 620-635.
58. Li, A.; Tian, Z.; Li, J.; Yu, R.; Banack, S.A.; Wang, Z. Detection of the neurotoxin BMAA within cyanobacteria isolated from freshwater in China. Toxicon 2010, 55, 947-953.
59. Sienko, D.G.; Davis, J.P.; Taylor, J.A.; Brooks, B.R. Amyotrophic lateral sclerosis. A case-control study following detection of a cluster in a small Wisconsin community. Arch. Neurol. 1990, 47, 38-41.
60. Sabel, C.E.; Boyle, P.J.; Löytönen, M.; Gatrell, A.C.; Jokelainen, M.; Flowerdew, R.; Maasilta, P. Spatial clustering of ALS in Finland at place of birth and place of death. Am. J. Epidemiol. 2003, 157, 898-905.
61. Caller, T.A.; Doolin, J.W.; Haney, J.F.; Murby, A.J.; West, K.G.; Farrar, H.E.; Ball, A.; Harris, B.T.; Stommel, E.W. A cluster of amyotrophic lateral sclerosis in New Hampshire: A possible role for toxic cyanobacteria blooms. Amyotroph. Lateral Scler. 2009, 10, 101-108.
62. Sieh, W.; Choi, Y.; Chapman, N.H.; Craig, U.K.; Steinbart, E.J.; Rothstein, J.H.; Garruto, R.M.; Bird, T.D.; Galasko, D.R.; Schellenberg, G.D. et al. Identification of novel susceptibility loci for Guam neurodegenerative disease: Challenges of genome scans in genetic isolates. Hum. Mol. Genet. 2009, 18, 3725-3738.
63. Wilson, J.M., Petrik, M.S., Moghadasian M.H., Shaw, C.A. Examining the interaction of apo E and neurotoxicity on a murine model of ALS-PDC. Can. J. Physiol. Pharm. 2005, 83, 131-141.
64. Sundar, P.D.; Yu, C.E.; Sieh, W.; Steinbart, E.; Garruto, R.M.; Oyanagi, K.; Craig, U.K.; Bird, T.D.; Wijsman, E.M.; Galasko, D.R. et al. Two sites in the MAPT region confer genetic risk for Guam ALS/PDC and dementia. Hum. Mol. Genet. 2007, 16, 295-306.
65. Smith, Q.R.; Nagura, H.; Takada, Y.; Duncan, M.W. Facilitated transport of the neurotoxin, β-N-methylamino-L-alanine, across the blood-brain barrier. J. Neurochem. 1992, 58, 1330-1337.
66. Lee, J.W.; Beebe, K.; Nangle, L.A.; Jang, J.; Longo-Guess, C.M.; Cook, S.A.; Davisson, M.T.; Sundberg, J.P.; Schimmel, P.; Ackerman, S.L. Editing-defective tRNA synthetase causes protein misfolding and neurodegeneration. Nature 2006, 443, 50-55.
67. Roos, P.M.; Vesterberg, O.; Syversen, T.; Peder Flaten, T.; Nordberg, M. Metal concentrations in cerebrospinal fluid and blood plasma from patients with amyotrophic lateral sclerosis. Biol. Trace Elem. Res. 2013, 151, 159-170.
68. Bergomi, M.; Vinceti, M.; Nacci, G.; Pietrini, V.; Brätter, P.; Alber, D.; Ferrari, A.; Vescovi, L.; Guidetti, D.; Sola, P. et al. Environmental exposure to trace elements and risk of amyotrophic lateral sclerosis: A population-based case-control study. Environ. Res. 2002, 89, 116-123.
69. Vinceti, M.; Guidetti, D.; Bergomi, M.; Caselgrandi, E.; Vivoli, R.; Olmi, M.; Rinaldi, L.; Rovesti, S.; Solime, F. Lead, cadmium, and selenium in the blood of patients with sporadic amyotrophic lateral sclerosis. Ital. J. Neurol. Sci. 1997, 18, 87-92.
70. Campbell, A.M.; Williams, E.R.; Barltrop, D. Motor neurone disease and exposure to lead. J. Neurol. Neurosurg. Psychiatry 1970, 33, 877-885.
71. Kamel, F.; Umbach, D.M.; Hu, H.; Munsat, T.L.; Shefner, J.M.; Taylor, J.A.; Sandler, D.P. Lead exposure as a risk factor for amyotrophic lateral sclerosis. Neurodegener. Dis. 2005, 2, 195-201.
72. Barbeito, A.G.; Guelfi, N.; Varga, M.R.; Pehar, M.; Beckman, J.; Barbeito, L.; Cassina, P. Chronic low-level lead exposure increases survival of G93A SOD-1 transgenic mice. In Amyotrophic lateral sclerosis: Beyond the motor neuron, Proceedings of the International Symposium, CasaPueblo/Punta del Este, Uruguay, 30 March-2 April 2005.
73. Kamel, F.; Umbach, D.M.; Stallone, L.; Richards, M.; Hu, H.; Sandler, D.P. Association of lead exposure with survival in amyotrophic lateral sclerosis. Environ. Health Perspect. 2008, 116, 943-947.
74. Daniele, L.; Garzillo, E.; Trojsi, F.; Monsurrò, M.; Tedeschi, G. Role of Occupational and Environmental Exposure to Heavy Metals in Amyotrophic Lateral Sclerosis: A Case-control Study in Campania Region. In Neurol. Sciences, Proceedings of the 43rd Congress of the Italian Neurological Society, Rimini, Italy, 6-9 October 2012; Springer-Verlag Italia: Milan, Italy, 2012.
75. Albalak, R.; McElroy, R.H.; Noonan, G.; Buchanan, S.; Jones, R.L.; Flanders, W.D.; Gotway-Crawford, C.; Kim, D.; Dignam, T.; Daley, W.R.; et al. Blood lead levels and risk factors for lead poisoning among children in a Mexican smelting community. Arch. Environ. Health 2003, 58, 172-183.
76. Oh, S.S.; Kim, E.A.; Lee, S.W.; Kim, M.K.; Kang, S.K. A case of amyotrophic lateral sclerosis in electronic parts manufacturing worker exposed to lead. Neurotoxicology 2007, 28, 324-327.
77. Yan, D.; Xiao, C.; Ma, F.L.; Wang, L.; Luo, Y.Y.; Liu, J.; Wang, H.L.; Chen, J.T.; Ruan, D.Y. Excitatory effects of low-level lead exposure on action potential firing of pyramidal neurons in CA1 region of rat hippocampal slices. J. Neurosci. Res. 2008, 86, 3665-3673.
78. Fang, F.; Kwee, L.C.; Allen, K.D.; Umbach, D.M.; Ye, W.; Watson, M.; Keller, J.; Oddone, E.Z.; Sandler, D.P.; Schmidt, S. et al. Association between blood lead and the risk of amyotrophic lateral sclerosis. Am. J. Epidemiol. 2010, 171, 1126-1133.
79. Luo, W.; Ruan, D.; Yan, C.; Yin, S.; Chen, J. Effects of chronic lead exposure on functions of nervous system in Chinese children and developmental rats. Neurotoxicology 2012, 33, 862-871.
80. Conradi, S.; Ronnevi, L.O.; Vesterberg, O. Abnormal tissue distribution of lead in amyo-trophic lateral sclerosis. J. Neurol. Sci. 1976, 29, 259-265.
81. Barbeito, A.G.; Cassina, P. Lead exposure stimulates VEGF expression in the spinal cord and extends survival in a mouse model of ALS. Neurobiol. Dis. 2010, 37, 574-580.
82. Kamel, F.; Umbach, D.M.; Lehman, T.A.; Park, L.P.; Munsat, T.L.; Shefner, J.M.; Sandler, D.P.; Hu, H.; Taylor, J.A. Amyotrophic lateral sclerosis, lead, and genetic susceptibility: Polymorphisms in the delta-aminolevulinic acid dehydratase and vitamin D receptor genes. Environ. Health Perspect. 2003, 111, 1335-1339.
83. Pilsner, J.R.; Hu, H.; Ettinger, A.; Sánchez, B.N.; Wright, R.O.; Cantonwine, D.; Lazarus, A.; Lamadrid-Figueroa, H.; Mercado-García, A.; Téllez-Rojo, M.M. et al. Influence of prenatal lead exposure on genomic methylation of cord blood DNA. Environ. Health Perspect. 2009, 117, 1466-1471.
84. Díez, S. Human health effects of methylmercury exposure. Rev. Environ. Contam. Toxicol. 2009, 198, 111-132.
85. Adams, C.R.; Ziegler, D.K.; Lin, J.T. Mercury intoxication simulating amyotrophic lateral sclerosis. JAMA 1983, 250, 642-643.
86. Provinciali, L.; Giovagnoli, A.R. Antecedent events in amyotrophic lateral sclerosis: Do they influence clinical onset and progression? Neuroepidemiology 1990, 9, 255-262.
87. Praline, J.; Guennoc, A.; Limousin, N.; Hallak, H.; de Toffol, B.; Corcia, P. Case report; ALS and mercury intoxication: A relationship? Clin. Neurol. Neurosurg. 2007, 109, 880-883.
88. Schwarz, S.; Husstedt, I.; Bertram, H.P.; Kuchelmeister, K. Amyotrophic lateral sclerosis after accidental injection of mercury. J. Neurol. Neurosurg. Psychiatry 1996, 60, 698.
89. Barber, T.E. Inorganic mercury intoxication reminiscent of amyotrophic lateral sclerosis. J. Occup. Med. 1978, 20, 667-669.
90. Pamphlett, R.; Waley, P. Mercury in human spinal motor neurons. Acta Neuropathol. 998, 96, 515-519.
91. Gresham, L.S.; Molgaard, C.A.; Golbeck, A.L.; Smith, R. Amyotrophic lateral sclerosis and occupational heavy metal exposure: A case-control study. Neuroepidemiology 1986, 5, 29-38.
92. Moriwaka, F.; Tashiro, K.; Doi, R.; Satoh, H.; Fukuchi, Y. A clinical evaluation of the inorganic mercurialism-Its pathogenic relation to amyotrophic lateral sclerosis. Rinsho Shinkeigaku 1991, 31, 885-887.
93. Arvidson, B. Inorganic mercury is transported from muscular nerve terminals to spinal and brainstem motoneurons. Muscle Nerve 1992, 15, 1089-1094.
94. Chuu, J.J.; Liu, S.H.; Lin-Shiau, S.Y. Differential neurotoxic effects of methylmercury and mercuric sulfide in rats. Toxicol. Lett. 2007, 169, 109-120.
95. th Annual Meeting and ToxExpo™, Baltimore, MD, USA, 15-19 March 2009; Oxford University Press, Society of Toxicology: Reston, VA, USA, 2009.
96. Bassett, T.; Bach, P.; Chan, H.M. Effects of methylmercury on the secretion of pro-inflammatory cytokines from primary microglial cells and astrocytes. Neurotoxicology 2012, 33, 229-234.
97. Choonara, Y.A.; Pillay, V.; du Toit, L.C.; Modi, G.; Naidoo, D.; Ndesendo, V.M.K.; Sibambo, S.R. Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders. Int. J. Mol. Sci. 2009, 10, 2510-2557.
98. L'Episcopo, F.; Tirolo, C.; Testa, N.; Caniglia, S.; Morale, M.C.; Marchetti, B. Glia as a turning point in the therapeutic strategy of Parkinson's disease. CNS Neurol. Disord. Drug Targets 2010, 9, 349-372.
99. Philips, T.; Robberecht, W. Neuroinflammation in amyotrophic lateral sclerosis: Role of glial activation in motor neuron disease. Lancet Neurol. 2011, 10, 253-263.
100. Bridges, C.; Zalups, R.K. Molecular and ionic mimicry and the transport of toxic metals. Toxicol. Appl. Pharmacol. 2005, 204, 274-308.
101. Rooney, J. Further thoughts on mercury, epigenetics, genetics and amyotrophic lateral sclerosis. Neurodegener. Dis. 2011, 8, 523-524.
102. Kilness, A.W.; Hochberg, F.H. Amyotrophic lateral sclerosis in a high selenium environment. JAMA 1977, 237, 2843-2844.
103. Vinceti, M.; Guidetti, D.; Pinotti, M.; Rovesti, S.; Merlin, M.; Vescovi, L.; Bergomi, M.; Vivoli, G. Amyotrophic lateral sclerosis after long-term exposure to drinking water with high selenium content. Epidemiology 1996, 7, 529-532.
104. Yang, G.Q.; Wang, S.Z.; Zhou, R.H.; Sun, S.Z. Endemic selenium intoxication of humans in China. Am. J. Clin. Nutr. 1983, 37, 872-881.
105. Vinceti, M.; Maraldi, T.; Bergomi, M.; Malagoli, C. Risk of chronic low-dose selenium overexposure in humans: Insights from epidemiology and biochemistry. Rev. Environ. Health 2009, 24, 231-248.
106. Matsumura, H.; Takahata, R.; Hayaishi, O. Inhibition of sleep in rats by inorganic selenium compounds, inhibitors of prostaglandin D synthase. Proc. Natl. Acad. Sci. USA 1991, 88, 9046-9050.
107. Nehru, B.; Iyer, A. Effect of selenium on lead-induced neurotoxicity in different brain regions of adult rats. J. Environ. Pathol. Toxicol. Oncol. 1994, 13, 265-268.
108. Rasekh, H.R.; Soliman, K.F.A.; Davis, M.D. Effect of selenium on central nervous system of male S-D rats: Evidences for neurotoxicity of selenium. Toxicol. Lett. 1998, 95, 64.
109. Tsunoda, M.; Johnson, V.J.; Sharma, R.P. Increase in dopamine metabolites in murine striatum after oral exposure to inorganic but not organic form of selenium. Arch. Environ. Contam. Toxicol. 2000, 39, 32-37.
110. Nogueira, C.W.; Meotti, F.C.; Curte, E.; Pilissao, C.; Zeni, G.; Rocha, J.B. Investigations into the potential neurotoxicity induced by diselenides in mice and rats. Toxicology 2003, 183, 29-37.
111. Liu, S.H.; Fu, W.M.; Lin-Shiau, S.Y. Effects of sodium selenite on neuromuscular junction of the mouse phrenic nerve-diaphragm preparation. Neuropharmacology 1989, 28, 733-739.
112. Lin-Shiau, S.Y.; Liu, S.H.; Fu, W.M. Neuromuscular actions of sodium selenite on chick biventer cervicis nerve-muscle preparation. Neuropharmacology 1990, 29, 493-501.
113. Togna, G.; Russo, P.; Pierconti, F.; Caprino, L. Effects of sodium selenite on vascular smooth muscle reactivity. Pharmacol. Res. 2000, 41, 195-199.
114. Ayaz, M.; Dalkilic, N.; Bariskaner, H.; Tuncer, S.; Demirel, I. Gender-dependent effects of selenite on the perfused rat heart: A toxicological study. Biol. Trace Elem. Res. 2007, 116, 301-310.
115. Davidson-York, D.; Galey, F.D.; Blanchard, P.; Gardner, I.A. Selenium elimination in pigs after an outbreak of selenium toxicosis. J. Vet. Diagn. Invest. 1999, 11, 352-357.
116. Casteignau, A.; Fontán, A.; Morillo, A.; Oliveros, J.A.; Segalés, J. Clinical, pathological and toxicological findings of a iatrogenic selenium toxicosis case in feeder pigs. J. Vet. Med. A 2006, 53, 323-326.
117. Vinceti, M.; Wei, E.T.; Malagoli, C.; Bergomi, M.; Vivoli, G. Adverse health effects of selenium in humans. Rev. Environ. Health 2001, 16, 233-251.
118. Maag, D.D.; Orsborn, J.S.; Clopton, J.R. The effect of sodium selenite on cattle. Am. J. Vet. Res. 1960, 21, 1049-1053.
119. Estevez, A.O.; Mueller, C.L.; Morgan, K.L.; Szewczyk, N.J.; Teece, L.; Miranda-Vizuete, A.; Estevez, M. Selenium induces cholinergic motor neuron degeneration in Caenorhabditis elegans. Neurotoxicology 2012, 33, 1021-1032.
120. Maraldi, T.; Riccio, M.; Zambonin, L.; Vinceti, M.; de Pol, A.; Hakim, G. Low levels of selenium compounds are selectively toxic for a human neuron cell line through ROS/RNS increase and apoptotic process activation. Neurotoxicology 2011, 32, 180-187.
121. Bendotti, C.; Carrì, M.T. Amyotrophic lateral sclerosis: Mechanisms and countermeasures. Antioxid. Redox Signal. 2009, 11, 1519-1522.
122. Frederickson, C.J.; Koh, J.Y.; Bush, A.I. The neurobiology of zinc in health and disease. Nat. Rev. Neurosci. 2005, 6, 449-462.
123. Sensi, S.L.; Jeng, J.M. Rethinking the excitotoxic ionic milieu: The emerging role of Zn2+ in ischemic neuronal injury. Curr. Mol. Med. 2004, 4, 87-111.
124. Yao, X. Effect of zinc exposure on HNE and GLT-1 in spinal cord culture. Neurotoxicology 2009, 30, 121-126.
125. Nutini, M.; Frazzini, V.; Marini, C.; Spalloni, A.; Sensi, S.L.; Longone, P. Zinc pre-treatment enhances NMDAR-mediated excitotoxicity in cultured cortical neurons from SOD1G93A mouse, a model of amyotrophic lateral sclerosis. Neuropharmacology 2011, 60, 1200-1208.
126. Groeneveld, G.J.; de van Leeuw Weenen, J., van Muiswinkel, F.L., Veldman, H., Veldink, J.H., Wokke, J.H., Bär, P.R., van den Berg, L.H. Zinc amplifies mSOD1-mediated toxicity in a transgenic mouse model of amyotrophic lateral sclerosis. Neurosci. Lett. 2003, 352, 175-178.
127. Ermilova, P.I.; Ermilov, B.V.; Levy, M.; Hob, E.; Pereira, C.; Beckman, S.B. Protection by dietary zinc in ALS mutant G93A SOD transgenic mice. Neurosci. Lett. 2005, 379, 42-46.
128. Ahtoniemi, T.; Goldsteins, G.; Keksa-Goldsteine, V.; Malm, T.; Kanninen, K.; Salminen A.; Koistinaho, J. Pyrrolidine dithiocarbamate inhibits induction of immunoproteasome and decreases survival in a rat model of amyotrophic lateral sclerosis. Mol. Pharmacol. 2007, 71, 30-37.
129. Li, Q.X.; Mok, S.S.; Laughton, K.M.; McLean, C.A.; Volitakis, I.; Cherny, R.A.; Cheung, N.S.; White, A.R.; Masters, C.L. Overexpression of Abeta is associated with acceleration of onset of motor impairment and superoxide dismutase 1 aggregation in an amyotrophic lateral sclerosis mouse model. Aging Cell 2006, 5, 153-165.
130. Tokuda, E.; Ono, S.; Ishige, K.; Naganuma, A.; Ito, Y.; Suzuki, T. Metallothionein proteins expression, copper and zinc concentrations, and lipid peroxidation level in a rodent model for amyotrophic lateral sclerosis. Toxicology 2007, 229, 33-41.
131. Hayward, L.J.; Rodriguez, J.A.; Kim, J.W.; Tiwari, A.; Goto, J.J.; Cabelli, D.E.; Valentine, J.S.; Brown, R.H., Jr. Decreased metallation and activity in subsets of mutant superoxide dismutases associated with familial amyotrophic lateral sclerosis. J. Biol. Chem. 2002, 277, 15923-159231.
132. Valentine, J.S.; Hart, P.J. Misfolded, CuZn SOD and amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA 2003, 100, 3617-3622.
133. Hart, P.J. Pathogenic superoxide dismutase structure, folding, aggregation and turnover. Curr. Opin. Chem. Biol. 2006, 10, 131-138.
134. Martyshkin, D.V.; Mirov, S.B.; Zhuang, Y.X.; Crow, J.P.; Ermilov, V.; Beckman, J.S. Fluorescence assay for monitoring Zn-deficient superoxide dismutase in vitro. Spectrochim. Acta A 2003, 59, 3165-3175.
135. Estévez, A.G.; Crow, J.P.; Sampson, J.B.; Reiter, C.; Zhuang, Y.; Richardson, G.J.; Tarpey, M.M.; Barbeito, L.; Beckman, J.S. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science 1999, 286, 2498-2500.
136. Goto, J.J.; Gralla, E.B.; Valentine, J.S.; Cabelli, D.E. Reactions of hydrogen peroxide with familial amyotrophic lateral sclerosis mutant human copper-zinc superoxide dismutases studied by pulse radiolysis. J. Biol. Chem. 1998, 273, 30104-30109.
137. Rivera-Mancía, S.; Pérez-Neria, I.; Ríos, C.; Tristán-López, L.; Rivera-Espinosa, L.; Montes, S. The transition metals copper and iron in neurodegenerative diseases. Chem. Biol. Interact. 2010, 186, 184-199.
138. Ji, H.F.; Shen, L.; Zhang, H.Y. Beta-lactam antibiotics are multipotent agents to combat neurological diseases. Biochem. Biophys. Res. Commun. 2005, 333, 661-663.
139. Hottinger, A.F.; Fine, E.G.; Gurney, M.E.; Zurn, A.D.; Aebischer, P. The copper chelator d-penicillamine delays onset of disease and extends survival in a transgenic mouse model of familial amyotrophic lateral sclerosis. Eur. J. Neurosci. 1997, 9, 1548-1551.
140. Andreassen, O.A.; Dedeoglu, A.; Klivenyi, P.; Beal, M.F.; Bush, A.I. N-acetyl-l-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. Neuroreport 2000, 11, 2491-2493.
141. Ho, Y.S.; Yang, X.; Yeung, S.C.; Chiu, K.; Lau, C.F.; Tsang, A.W.; Mak, J.C.; Chang, R.C. Cigarette smoking accelerated brain aging and induced pre-Alzheimer-like neuropathology in rats. PLoS One 2012, 7, e36752.
142. Weisskopf, M.G.; Grodstein, F.; Ascherio, A. Smoking and cognitive function in Parkinson's disease. Mov. Disord. 2007, 22, 660-665.
143. Alonso, A.; Logroscino, G.; Hernán, M.A. Smoking and the risk of amyotrophic lateral sclerosis: A systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry 2010, 81, 1249-1252.
144. Wang, H.; O'Reilly, E.J.; Weisskopf, M.G.; Logroscino, G.; McCullough, M.L.; Thun, M.J.; Schatzkin, A.; Kolonel, L.N.; Ascherio, A. Smoking and risk of amyotrophic lateral sclerosis: A pooled analysis of 5 prospective cohorts. Arch. Neurol. 2011, 68, 207-213.
145. De Jong, S.W.; Huisman, M.H.B.; Sutedja, N.A.; van der Kooi, A.J.; de Visser, M.; Schelhaas, H.J.; Fischer, K.; Veldink, J.H.; van den Berg, L.H. Smoking, alcohol consumption, and the risk of amyotrophic lateral sclerosis: A population-based study. Am. J. Epidemiol. 2012, 176, 233-239.
146. Fang, F.; Bellocco, R.; Hernán, M.A.; Ye, W. Smoking, snuff dipping and the risk of amyotrophic lateral sclerosis-a prospective cohort study. Neuroepidemiology 2006, 27, 217-221.
147. Djordjevic, M.V.; Fan, J.; Hoffmann, D. Assessment of chlorinated pesticide residues in cigarette tobacco based on supercritical fluid extraction and GC-ECD. Carcinogenesis 1995, 16, 2627-2632.
148. Hoffmann, D.; Hoffmann, I.; El-Bayoumy, K. The less harmful cigarette: A controversial issue. A tribute to Ernst L. Wynder. Chem. Res. Toxicol. 2001, 14, 767-790.
149. Morselt, A.F. Environmental pollutants and diseases. A cell biological approach using chronic cadmium exposure in the animal model as a paradigm case. Toxicology 1991, 70, 1-132.
150. Huang, Y.H.; Shih, C.M.; Huang, C.J.; Lin, C.M.; Chou, C.M.; Tsai, M.L.; Liu, T.P.; Chiu, J.F.; Chen, C.T. Effects of cadmium on structure and enzymatic activity of Cu,Zn-SOD and oxidative status in neural cells. J. Cell. Biochem. 2006, 98, 577-589.
151. Bauer, R.; Demeter, I.; Hasemann, V.; Johansen, J.T. Structural properties of the zinc site in Cu,Zn-superoxide dismutase; perturbed angular correlation of gamma ray spectroscopy on the Cu, 111Cd-superoxide dismutase derivative. Biochem. Biophys. Res. Commun. 1980, 94, 1296-1302.
152. Kofod, P.; Bauer, R.; Danielsen, E.; Larsen, E.; Bjerrem, M.J. 113Cd-NMR investigation of a cadmium-substituted copper, zinc-containing superoxide dismutase from yeast. Eur. J. Biochem. 1991, 198, 607-611.
153. Bar-Sela, S.; Reingold, S.; Richter, E.D. Amyotrophic lateral sclerosis in a battery-factory worker exposed to cadmium. Int. J. Occup. Environ. Health 2001, 7, 109-112.
154. Gurel, A.; Coskun, O.; Armutcu, F.; Kanter, M.; Ozen, O.A. Vitamin E against oxidative damage caused by formaldehyde in frontal cortex and hippocampus: Biochemical and histological studies. J. Chem. Neuroanat. 2005, 29, 173-178.
155. Nie, C.L.; Wang, X.S.; Liu, Y.; Perrett, S.; He, R.Q. Amyloid-like aggregates of neuronal tau induced by formaldehyde promote apoptosis of neuronal cells. BMC Neurosci. 2007, 8, 9.
156. Strubelt, O.; Younes, M.; Pentz, R.; Kühnel, W. Mechanistic study on formaldehyde-induced hepatotoxicity. J. Toxicol. Environ. Health 1989, 27, 351-366.
157. Ticozzi, N.; LeClerc, A.L.; Keagle, P.; Glass, J.D.; Wills, A.M.; van Blitterswijk, M.; Bosco, D.A.; Rodriguez-Leyva, I.; Gellera, C.; Ratti, A. et al. Paraoxonase gene mutations in amyotrophic lateral sclerosis. Ann. Neurol. 2010, 68, 102-107.
158. Imaizumi, T.; Higaki, Y.; Hara, M.; Sakamoto, T.; Horita, M.; Mizuta, T.; Eguchi, Y.; Yasutake, T.; Ozaki, I.; Yamamoto, K. et al. Interaction between cytochrome P450 1A2 genetic polymorphism and cigarette smoking on the risk of hepatocellular carcinoma in a Japanese population. Carcinogenesis 2009, 30, 1729-1734.
159. Boccia, S.; Sayed-Tabatabaei, F.A.; Persiani, R.; Gianfagna, F.; Rausei, S.; Arzani, D.; La Greca, A.; D'Ugo, D.; La Torre, G.; van Duijn, C.M. et al. Polymorphisms in metabolic genes, their combination and interaction with tobacco smoke and alcohol consumption and risk of gastric cancer: A case-control study in an Italian population. BMC Cancer 2007, 7, 206.
160. Diekstra, F.P.; Saris, C.G.J.; van Rheenen, W.; Franke, L.; Jansen, R.C.; van Es, M.A.; van Vught, P.W.J.; Blauw, H.M.; Groen, E.J.N.; Horvath, S. et al Mapping of gene expression reveals CYP27A1 as a susceptibility gene for sporadic ALS. PLoS One 2012, 7, e35333.
161. Zhou, H.; Chen, G.; Chen, C.; Yu, Y.; Xu, Z. Association between extremely low-frequency electromagnetic fields occupations and amyotrophic lateral sclerosis: A meta-analysis. PLoS One 2012, 7, e48354.
162. Abhinav, K.; Al-Chalabi, A.; Hortobagyi, T.; Leigh, P.N. Electrical injury and amyotrophic lateral sclerosis: A systematic review of the literature. J. Neurol. Neurosurg. Psychiatry 2007, 78, 450-453.
163. Falone, S.; Mirabilio, A.; Carbone, M.C.; Zimmitti, V.; di Loreto, S.; Mariggiò, M.A.; Mancinelli, R.; di Ilio, C.; Amicarelli, F. Chronic exposure to 50 Hz magnetic fields causes a significant weakening of antioxidant defence systems in aged rat brain. Int. J. Biochem. Cell. Biol. 2008, 40, 2762-2770.
164. Martinez-Samano, J.; Torres-Duran, P.V.; Juarez-Oropeza, M.A.; Verdugo-Diaz, L. Effect of acute extremely low frequency electromagnetic field exposure on the antioxidant status and lipid levels in rat brain. Arch. Med. Res. 2012, 43, 183-189.
165. Poulletier de Gannes, F.; Ruffié, G.; Taxile, M.; Ladevèze, E.; Hurtier, A.; Haro, E.; Duleu, S.; Charlet de Sauvage, R.; Billaudel, B.; Geffard, M. et al. Amyotrophic lateral sclerosis (ALS) and extremely-low frequency (ELF) magnetic fields: A study in the SOD-1 transgenic mouse model. Amyotroph. Lateral. Scler. 2009, 10, 370-373.
166. Elbaz, A.; Dufouil, C.; Alpérovitch, A. Interaction between genes and environment in neurodegenerative diseases. C. R. Biol. 2007, 330, 318-328.
167. Stozická, Z.; Zilka, N.; Novák, M. Risk and protective factors for sporadic Alzheimer's disease. Acta Virol. 2007, 51, 205-222.
168. Savettieri, G.; Salemi, G.; Arcara, A.; Cassata, M.; Castiglione, M.G.; Fierro, B. A case-control study of amyotrophic lateral sclerosis. Neuroepidemiology 1991, 10, 242-245.
169. Gunnarsson, L.G.; Bodin, L.; Soderfeldt, B.; Axelson, O. A case-control study of motor neurone disease-Its relation to heritability, and occupational exposures, particularly to solvents. Br. J. Ind. Med. 1992, 49, 791-798.
170. Chancellor, A.M.; Slattery, J.M.; Fraser, H.; Warlow, C.P. Risk factors for motor neuron disease-A case-control study based on patients from the Scottish motor neuron disease register. J. Neurol. Neurosurg. Psychiatry 1993, 56, 1200-1206.
171. McGuire, V.; Longstreth, W.T., Jr.; Nelson, L.M.; Koepsell, T.D.; Checkoway, H.; Morgan, M.S.; van Belle, G. Occupational exposures and amyotrophic lateral sclerosis: A population-based case-control study. Am. J. Epidemiol. 1997, 145, 1076-1088.
172. Bonvicini, F.; Marcello, N.; Mandrioli, J.; Pietrini, V.; Vinceti, M. Exposure to pesticides and risk of amyotrophic lateral sclerosis: A population-based case-control study. Ann. Ist. Super. Sanità 2010, 46, 284-287.
173. Kamel, F.; Umbach, D.M.; Bedlack, R.S.; Richards, M.; Watson, M.; Alavanja, M.C.R.; Blair, A.; Hoppin, J.A.; Schmidt, S.; Sandler, D.P. Pesticide exposure and amyotrophic lateral sclerosis. Neurotoxicology 2012, 33, 457-462.
174. Burns, C.J.; Beard, K.K.; Cartmill, J.B. Mortality in chemical workers potentially exposed to 2,4-dichlorophenoxyacetic acid (2,4-D) 1945-94: An update. Occup. Environ. Med. 2001, 58, 24-30.
175. Granieri, E.; Carreras, M.; Tola, R.; Paolino, E.; Tralli, G.; Eleopra, R.; Serra, G. Motor neuron disease in the province of Ferrara, Italy, in 1964-1982. Neurology 1988, 38, 1604-1608.
176. Malek, A.M.; Barchowsky, A.; Bowser, R.; Youk, A.; Talbott, E.O. Pesticide exposure as a risk factor for amyotrophic lateral sclerosis: A meta-analysis of epidemiological studies: Pesticide exposure as a risk factor for ALS. Environ. Res. 2012, 117, 112-119.
177. Weiss, B.; Amler, S.; Amler, W.R. Pesticides. Pediatrics 2004, 113, 1030-1036.
178. Chen, Y. Organophosphate-induced brain damage: Mechanisms, neuropsychiatric and neurological consequences, and potential therapeutic strategies. Neurotoxicology 2012, 33, 391-400.
179. Morahan, J.M.; Yu, B.; Trent, R.J.; Pamphlett, R. Genetic susceptibility to environmental toxicants in ALS. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 2007, 144B, 885-890.
180. Wills, A.M.; Landers, J.E.; Zhang, H.; Richter, R.J.; Caraganis, A.J.; Cudkowicz, M.E.; Furlong, C.E.; Brown, R.H., Jr. Paraoxonase 1 (PON1) organophosphate hydrolysis is not reduced in ALS. Neurology 2008, 70, 929-934.
181. Costa, L.G.; Giordano, G.; Cole, T.B.; Marsillach, J.; Furlong, C.E. Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity. Toxicology 2013, 307, 115-122.
182. Landers, J.E.; Shi, L.; Cho, T.J.; Glass, J.D.; Shaw, C.E.; Leigh, P.N.; Diekstra, F.; Polak, M.; Rodriguez-Leyva, I.; Niemann, S. et al. A common haplotype within the PON1 promoter region is associated with sporadic ALS. Amyotroph. Lateral Scler. 2008, 9, 306-314.
183. Richter, R.J.; Jarvik, G.P.; Furlong, C.E. Paraoxonase 1 (PON1) status and substrate hydrolysis. Toxicol. Appl. Pharmacol. 2009, 235, 1-9.
184. Saeed, M.; Siddique, N.; Hung, W.Y.; Usacheva, E.; Liu, E.; Sufit, R.L.; Heller, S.L.; Haines, J.L.; Pericak-Vance, M.; Siddique T. Paraoxonase cluster polymorphisms are associated with sporadic ALS. Neurology 2006, 67, 771-776.
185. Slowik, A.; Tomik, B.; Wolkow, P.P.; Partyka, D.; Turaj, W.; Malecki, M.T.; Pera, J.; Dziedzic, T.; Szczudlik, A.; Figlewicz, D.A. Paraoxonase gene polymorphisms and sporadic ALS. Neurology 2006, 67, 766-770.
186. Cronin, S.; Greenway, M.J.; Prehn, J.H.; Hardiman, O. Paraoxonase promoter and intronic variants modify risk of sporadic amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 2007, 78, 984-986.
187. Valdmanis, P.N.; Kabashi, E.; Dyck, A.; Hince, P.; Lee, J.; Dion, P.; D'Amour, M.; Souchon, F.; Bouchard, J.P.; Salachas, F. et al. Association of paraoxonase gene cluster polymorphisms with ALS in France, Quebec, and Sweden. Neurology 2008, 71, 514-520.
188. Simpson, C.L.; Al-Chalabi, A. Amyotrophic lateral sclerosis as a complex genetic disease. Biochim. Biophys. Acta 2006, 1762, 973-985.
189. Van Blitterswijk, M.; Blokhuis, A.; van Es, M.A.; van Vught, P.W.; Rowicka, P.A.; Schelhaas, H.J.; van der Kooi, A.J.; de Visser, M.; Veldink, J.H.; van den Berg, L.H. Rare and common paraoxonase gene variants in amyotrophic lateral sclerosis patients. Neurobiol. Aging 2012, 33, 1845.e1-1845.e3.
190. Vinceti, M.; Fiore, M.; Signorelli, C.; Odone, A.; Tesauro, M.; Consonni, M.; Arcolin, E.; Malagoli, C.; Mandrioli, J.; Marmiroli, S. et al. Environmental risk factors for amyotrophic lateral sclerosis: Methodological issues in epidemiologic studies. Ann. Ig. 2012, 24, 407-415.
191. Qureshi, I.A.; Mehler, M.F. Advances in epigenetics and epigenomics for neurodegenerative diseases. Curr. Neurol. Neurosci. Rep. 2011, 11, 464-473.
192. Marques, S.C.F.; Oliveira, C.R.; Pereira, C.M.F.; Outeiro, T.F. Epigenetics in neurodegeneration: A new layer of complexity. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35, 348-355.